CD8A and neoplasm: In summary, we observed that >100 days after vaccination, prior to tumor challenge, mice vaccinated twice have significantly less blood resident OVA-specific CD8+ T cells (**, p < 0.01) (Figure 5A,B) but they expressed significantly more CD62L (***, p < 0.001) (Figure 5C,D) compared to mice vaccinated three times yet they had similar protection from a tumor challenge.